Panacea Sells 80k Atara Shares After FDA Letter: What It Means for the Biotech Market
Panacea Innovation’s January 2026 sale of 80,554 Atara Biotherapeutics shares highlights how insider moves, FDA setbacks and market strategy shape biotech valuations—and what investors and analysts should watch next.
4 minutes to read